biochimica clinica

it_IT Italian
it_IT Italian en_US English

RASSEGNE - Reviews

Volume:

Biochimica Clinica, 48 (3) pag 2011-223

Pubblicato on-line:

Luglio 2, 2024

DOI:

10.19186/BC_2024.034

Scarica in PDF:
Autenticazione richiesta

Determinazione e supplementazione della vitamina D: come, a chi e perché

AUTORI

Mario Plebani1,2, Martina Zaninotto2, Sandro Giannini3, Stefania Sella3, Maria Fusaro4, Giovanni Tripepi5, Maurizio Gallieni6, Markus Herrmann7, Mario Cozzolino8
1Università di Padova
2 QI.LAB.MED, Spin-off dell’Università di Padova
3Clinica Medica 1, Dipartimento di Medicina-DIMED, Università di Padova
4Istituto di Fisiologia Clinica del Consiglio Nazionale delle Ricerche (IFC-CNR), Pisa
5Istituto di Fisiologia Clinica del Consiglio Nazionale delle Ricerche (IFC-CNR), Reggio Calabria
6Dipartimento di Scienze Biomediche e Cliniche, Università di Milano
7Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Austria
8Dipartimento di Scienze della Salute, Università di Milano

ABSTRACT

Vitamin D assay and supplementation

In the last decades, in addition to improvements in the understanding of pathophysiology, mechanisms of action and role of vitamin D in bone metabolism, significant advancements in analytical methods and assay standardization have been reported. Advances in biochemical assessment, therapeutic goals for vitamin D nutrition for optimal bone health, and the association of vitamin D deficiency with non-skeletal disease have revived interest in this hormone. In addition, many papers, meta-analyses and recommendations on the clinical value of this vitamin and its supplementation to correct severe vitamin D deficiency have been published. However, particularly after the release of the “Determina” AIFA, it seems to be useful to clarify some essential variables of the vitamin D measurement (regarding both analytical and post-analytical issues), as well as current evidence on its supplementation. In addition, taking into consideration the interconnection between vitamin D, Parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23), a discussion on both analytical issues and clinical usefulness of their measurement will be discussed.

BIBLIOGRAFIA

BIBLIOGRAFIA

  1. Giuliani S, Barbieri V, Di Pierro AM, Rossi F, Widmann T, Lucchiari M et al. LC-MS/MS based 25(OH)D status in a large Southern European outpatient cohort: gender- and age-specific differences. Eur J Nutr 2019;58:2511-20.
  2. Stoica AB, Mărginean C. The impact of vitamin D deficiency on infants’ health. Nutrients 2023;15:4379.
  3. Christakos S, Dhawan P, Verstuyf A, Verlinden L, Carmeliet G. Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects. Physiol Rev 2016;96:365-408,
  4. Pilkey NG, Novosel O, Roy A, Wilson TE, Sharma J, Khan S et al. Does native vitamin D supplementation have pleiotropic effects in patients with End-Stage Kidney Disease? A systematic review of randomized Trials. Nutrients 2023;15:3072.,
  5. Cosentino N, Campodonico J, Milazzo V. Vitamin D and cardiovascular disease: current evidence and future perspectives. Nutrients 2021;13:3603.
  6. Agenzia Italiana del Farmaco, “Nota 96 per la prescrizione di farmaci a base di vitamina D,”. Allegato 1, 2023 https://www.aifa.gov.it/Nota-96. (ultimo accesso: maggio 2024)
  7. Holick MF. The use and interpretation of assays for vitamin D and its metabolites. J Nutr 1990;120 Suppl 11:1464-9.
  8. Lips P. Relative value of 25(OH)D and 1,25(OH)2D measurements. J Bone Miner Res 2007;22:1668-71.
  9. Amrein K, Scherkl M, Hoffmann M, Neuwersch-Sommeregger S, Köstenberger M, Tmava Berisha A, et al. Vitamin D deficiency 2.0: an update on the current status worldwide. Eur J Clin Nutr 2020;74:1498-513.
  10. Alonso N, Zelzer S, Eibinger G, Herrmann M. Vitamin D metabolites: analytical challenges and clinical relevance. Calcif Tissue Int 2023;112:158-77.
  11. Wallace AM, Gibson S, de la Hunty A, Lamberg-Allardt C, Ashwell M. Measurement of 25-hydroxyvitamin D in the clinical laboratory: current procedures, performance characteristics and limitations. Steroids 2010;75:477-88.
  12. Altieri B, Cavalier E, Bhattoa HP, Pérez-López FR, López-Baena MT, Pérez-Roncero GR et al. Vitamin D testing: advantages and limits of the current assays. Eur J Clin Nutr 2020;74:231-47.
  13. Bikle DD. Vitamin D assays. Front Horm Res 2018;50:14-30.
  14. Belsey R, DeLuca HF, Potts Jr JT Competitive binding assay for vitamin D and 25-OH vitamin D. J. Clin. Endocrinol Metab 1971;33:554-7.
  15. Bouillon R, Van Heck E, Jans I, Tan BK, Van Baelen H, De Moor P. Two direct (nonchromatographic) assays for 25-hydroxyvitamin D. Clin Chem 1984;30:1731-6.
  16. Le Goff C, Cavalier E, Souberbielle JC, González-Antuña A, Delvin E. Measurement of circulating 25-hydroxyvitamin D: a historical review. Pract Lab Med 2015;12:1-14.
  17. Centers for Disease Control and Prevention (CDC).Vitamin D Stardardization-Certification Program (VDSCP). Accessed April 24, 2024. https://www.cdc.gov/labstandards/csp/vdscp_procedures.htlm (ultimo accesso: maggio 2024)
  18. Binkley N, Dawson-Hughes B, Durazo-Arvizu R, Thamm M, Tian L, Merkel JM,et al. Vitamin D measurement standardization: The way out of the chaos. J Steroid Biochem Mol Biol 2017;173:117-21.
  19. Durazo-Arvizu RA, Tian L, Brooks SPJ, Sarafin K, Cashman KD, Kiely M et al. The Vitamin D standardization program (VDSP) manual for retrospective laboratory standardization of serum 25-Hydroxyvitamin D data. J AOAC Int 2017;100:1234-43.
  20. Briggs LE, Whitewood JK, Williams EL. Analytical variation concerning total 25-hydroxyvitamin D measurement, where are we now? A DEQAS review of current assay performance J Steroid Biochem Mol Biol 2023;231:106328.
  21. Herrmann M, Zelzer S, Cavalier E, Kleber M, Drexler-Helmberg C, Schlenke P et al. Functional assessment of vitamin D status by a novel metabolic approach: the low vitamin D profile concept. Clin Chem 2023;69:1307-16.
  22. Schwartz JB, Gallagher JC, Jorde R, Berg V, Walsh J , Eastell R et al. Determination of free 25(OH)D concentrations and their relationships to total 25(OH)D in multiple clinical populations. J Clin Endocrinol Metab 2018;103:3278-88.
  23. Nielson CM, Jones KS, Bouillon R, Osteoporotic Fractures in Men (MrOS) Research Group. Role of assay type in determining free 25-hydroxyvitamin D levels in diverse populations. N Engl J Med 2016;374:1695-6.
  24. Nielson CM, Jones KS, Chun RF, Jacobs JM, Wang Y, Hewison Met al. Free 25-hydroxyvitamin D: impact of vitamin D binding protein assays on racial-genotypic associations. J Clin Endocrinol Metab 2016;101:2226-34.
  25. El Sabeh M, Ghanem P, Al-Shaar L, Rahme M, Baddoura R,  Halaby  G et al. Total, bioavailable, and free 25(OH)D relationship with indices of bone health in elderly: a randomized controlled trial. J Clin Endocrinol Metab 2021;106:e990-e1001.
  26. Brumbaugh PF, Haussler DH, Bressler R, Haussler MR. Radioreceptor assay for 1 alpha,25-dihydroxyvitamin D3. Science1974;183:1089–91.
  27. Tsugawa N, Okano T. Bone and bone related biochemical examinations. Hormone and hormone related substances. Vitamin D (25D, 1,25D); measurements and clinical significances. Clin Calcium 2006;16:36–42.
  28. Hollis BW, Horst RL The assessment of circulating 25(OH)D and 1,25(OH)2D: where we are and where we are going. J Steroid Biochem Mol Biol 2007;103:473-6.
  29. Hussein H, Ibrahim F, Boudou P Evaluation of a new automated assay for the measurement of circulating 1,25-dihydroxyvitamin D levels in daily practice. Clin Biochem 2015; 48:1160– 2.
  30. Valcour A, Zierold C, Podgorski AL, Olson GT, Wall JV,  DeLuca  HF et al. A novel, fully-automated, chemiluminescent assay for the detection of 1,25-dihydroxyvitamin D in biological samples. J Steroid Biochem Mol Biol 2016; 164:120–6.
  31. Spanaus K, von Eckardstein A. Evaluation of two fully automated immunoassay based tests for the measurement of 1α,25-dihydroxyvitamin D in human serum and comparison with LC-MS/MS. Clin Chem Lab Med 2017;55:1305-14.
  32. Higgins V, Truong D, White-Al Habeeb NMA,  Fung AWS, Hoffman B, Adeli K. Pediatric reference intervals for 1,25-dihydroxyvitamin D using the DiaSorin LIAISON XL assay in the healthy CALIPER cohort. Clin Chem Lab Med 2018; 56:964–72.
  33. Souberbielle JC, Cavalier E, Delanaye P, Massart C, Brailly-Tabard S, Cormier C, et al. Serum calcitriol concentrations measured with a new direct automated assay in a large population of adult healthy subjects and in various clinical situations. Clin Chim Acta 2015;451:149-53.
  34. Adams JS, Hewison M. Extrarenal expression of the 25-hydroxyvitamin D-1-hydroxylase. Arch Biochem Biophys 2012;523:95-102.
  35. Goltzman D. Functions of vitamin D in bone. Histochem Cell Biol 2018;149:305–12.
  36. Janubová M, Žitňanová I. The effects of vitamin D on different types of cells. Steroids 2024;202:109350.
  37. Chang E. Vitamin D mitigates hepatic fat accumulation and inflammation and increases SIRT1/AMPK expression in AML-12 hepatocytes. Molecules 2024;29:1401.
  38. Makris K, Bhattoa HP, Cavalier E, Phinney K, Sempos CT, Ulmer CZ, et al, .Recommendations on the measurement and the clinical use of vitamin D metabolites and vitamin D binding protein – A position paper from the IFCC Committee on bone metabolism. Clin Chim Acta 2021; 517:171-97.
  39. Herrmann M. Assessing vitamin D metabolism – four decades of experience. Clin Chem Lab Med 2023;61:880-94.
  40. Giustina A, Bilezikian JP, Adler RA, Banfi G, Bikle DD, Binkley NC et al. Consensus statement on vitamin D status assessment and supplementation: whys, whens, and hows. Endocr Rev 2024 doi: 10.1210/endrev/bnae009 (ahead of print).
  41. Agoro R, White KE. Regulation of FGF23 production and phosphate metabolism by bone-kidney interactions. Nat Rev Nephrol 2023;19:185-93.
  42. Smit MA, van Kinschot CMJ, van der Linden J, van Noord C, Kos S. Clinical guidelines and PTH measurement: does assay generation matter? Endocr Rev 2019;40:1468-80.
  43. Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters. Kidney Int 2017;9:26-36.
  44. Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, et al. Diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder: synopsis of the kidney disease: Improving Global Outcomes 2017 Clinical Practice Guideline update. Ann Intern Med 2018;168:422-30.
  45. Valcour A, Zierold C, Blocki FA, Hawkins DM, Martin KJ, Rao SD et al. Trueness, precision and stability of the LIAISON 1-84 parathyroid hormone (PTH) third-generation assay: comparison to existing intact PTH assays. Clin Chem Lab Med 2018;56:1476-82.
  46. Einbinder Y, Benchetrit S, Golan E, Zitman-Gal T. Comparison of intact PTH and bio-intact PTH assays among non-dialysis dependent chronic kidney dis- ease patients. Ann Lab Med 2017;37:381–7.
  47. Gao P, Scheibel S, D’Amour P, John MR, Rao SD, Schmidt-Gayk H,et al. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1- 84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 2001;16:605–14.
  48. Sella S, Bonfante L, Fusaro M, Neri F, Plebani M, Zaninotto M et al. Efficacy of weekly administration of cholecalciferol on parathyroid hormone in stable kidney-transplanted patients with CKD stage 1-3. Clin Chem Lab Med 2020;59:343-51.
  49. Censi S, Iacobone M, Simmini S, Manso J, Franceschet G, Plebani M et al. PTH: Redefining reference ranges in a healthy population-the role of interfering factors and the type of laboratory assay. Int J Endocrinol 2020. doi: 10.1155/2020/1053719.
  50. Fusaro M, Barbuto S, Gallieni M, Cossettini A, Re Sartò GV, Cosmai L et al. Real-world usage of Chronic Kidney Disease – Mineral Bone Disorder (CKD-MBD) biomarkers in nephrology practices. Clin Kidney 2023;17:sfad290.
  51. Cavalier E, Schleck ML, Souberbielle JC. Spurious intraoperative PTH results observed with 2nd, but not with 3rd generation PTH assays. Clin Chim Acta 2018;477:72-3.
  52. Yamashita H, Gao P, Cantor T, Noguchi S, Uchino S, Watanabe S, et al. Comparison of parathyroid hormone levels from the intact and whole parathyroid hormone assays after parathyroidectomy for primary and secondary hyperparathyroidism. Surgery 2004;135:149-6.
  53. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003;348:1656-63.
  54. Donate-Correa J, Muros-de-Fuentes M, Mora-Fernández C, Navarro-González JF. FGF23/Klotho axis: phosphorus, mineral metabolism and beyond. Cytokine Growth Factor Rev 2012;23:37-46.
  55. Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R et al.; Evaluation of Cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial investigators. Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: Circulation 2015;132:27-39.
  56. Edmonston D, Grabner A, Wolf M. FGF23 and Klotho at the intersection of kidney and cardiovascular disease. Nat Rev Cardiol 2024 ;21:11-24.
  57. Edmonston D, Wolf M. FGF23 at the crossroads of phosphate, iron economy and erythropoiesis. Nat Rev Nephrol 2020;16:7-19.
  58. Smith ER, McMahon LP, Holt SG. Fibroblast growth factor 23. Ann Clin Biochem 2014;51:203-27.
  59. Ferraro S, Biganzoli G, Calcaterra V, Zuccotti G, Biganzoli EM, Plebani M. Fibroblast growth factor 23: translating analytical improvement into clinical effectiveness for tertiary prevention in chronic kidney disease. Clin Chem Lab Med 2022; 60:1694-705.
  60. Chiang C. The use of bone turnover markers in chronic kidney disease-mineral and bone disorders. Nephrol 2017;   Suppl 2:11-3.
  61. Lau WL, Obi Y, Kalantar-Zadeh K. Parathyroidectomy in the management of secondary hyperparathyroidism. Clin J Am Soc Nephrol 2018;13:952-61.
  62. Cannata-Andía JB, Martín-Carro B, Martín-Vírgala J,Rodríguez-Carrio J, Bande-Fernández JJ, Alonso-Montes C et al. Chronic kidney disease—mineral and bone disorders: pathogenesis and management. Calcif Tissue Int 2021;108:410-22.
  63. Rodríguez-Ortiz ME, Rodríguez M. Recent advances in understanding and managing secondary hyperparathyroidism in chronic kidney disease. F1000Res 2020;9:F1000 Faculty Rev-1077.
  64. Smout D, Jørgensen HS, Cavalier E, Evenepoel P. Clinical utility of bone turnover markers in patients with chronic kidney disease. Curr Opin Nephrol Hypertens 2022;31:332-8.
  65. Vilaca T, Salam S, SchiniM,Harnan S, Sutton A, Poku Eet al. Risks of hip and nonvertebral fractures in patients with CKD G3a-G5D: a systematic review and meta-analysis. Am J Kidney Dis 2020;76:521-32.
  66. Fusaro M, Tripepi G, Noale M, Vajente N, Plebani M, Zaninotto M  et al. High prevalence of vertebral fractures assessed by quantitative morphometry in hemodialysis patients, strongly associated with vascular calcifications. Calcif Tissue Int 2013;93:39-47.
  67. Castro-Alonso C, D’Marco L, Pomes J, Del Amo Conill M,  García-Diez AI , Pablo Molina P et al. Prevalence of vertebral fractures and their prognostic significance in the survival in patients with Chronic Kidney Disease Stages 3‒5 not on dialysis. J Clin Med 2020;9:1604.
  68. Schini M, Vilaca T, Gossiel F, Salam S , Eastell R. Bone turnover markers: basic biology to clinical applications. Endocr Rev 2023;44:417-3.
  69. Ginsberg C, Ix JH. Diagnosis and management of osteoporosis in advanced kidney disease: a review. Am J kidney Dis 2022;79:427-36.
  70. Salam S, Gallagher O, Gossiel F, Paggiosi M, Khwaja A, EastellR . Diagnostic accuracy of biomarkers and imaging for bone turnover in renal osteodystrophy. J Am Soc Nephrol 2018;29:1557–65.
  71. Jørgensen HS, Behets G, Viaene L, Bammens B, Claes K, Meijers B, Naesens M,et al. Diagnostic accuracy of noninvasive bone turnover markers in renal osteodystrophy. Am J Kidney Dis 2022;79:667-76.
  72. Haarhaus M, Cianciolo G, Barbuto S, La Manna G, , Gasperoni L,  Tripepi G et al. Alkaline phosphatase: an old friend as treatment target for cardiovascular and mineral bone disorders in chronic kidney disease. Nutrients 2022;14:2124.
  73. Maruyama Y, Taniguchi M, Kazama JJ, Yokoyama K,   Hosoya T, Yokoo Tet al. A higher serum alkaline phosphatase is associated with the incidence of hip fracture and mortality among patients receiving hemodial-ysis in Japan. Nephrol Dial Transplant 2014;29:1532-8.
  74. Iimori S, Mori Y, Akita W, Kuyama T, Takada S, Asai T et al. Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients–a single-center cohort study. Nephrol Dial Transplant 2012;27:345-51.
  75. Sridharan K. Chronic kidney disease mineral and bone disorder: A guide for general practice. Aust J Gen Pract 2023;52:52-7.
  76. LeBoff MS, Chou SH, Ratlif KA, Cook NR, Khurana B, Kim E, Cawthon PM, et al (2022) Supplemental vitamin D and incident fractures in midlife and older adults. N Engl J Med 2022;387:299-309.
  77. Bischoff-Ferrari HA, Vellas B, Rizzoli R, Kressig RW, da Silva JAP, Blauth M,et al.; DO-HEALTH research group. Effect of vitamin D supplementation, Omega-3 fatty acid supplementation, or a strength-training exercise program on clinical outcomes in older adults: The DO-HEALTH Randomized Clinical Trial. JAMA 2020;324:1855-68.
  78. SIOMMMS, Sintesi delle nuove raccomandazioni 2022 della Società Italiana dell’ Osteoporosi, del Metabolismo Minerale e Malattie dello Scheletro ( SIOMMMS ) per la gestione della carenza di vitamina D, 2022. https://www.siommms.it/wp-content/uploads/2023/03/Sintesi-nuove-raccomandazioni-SIOMMMS-2022-carenza-vitamina-D.pdf (ultimo accesso: maggio 2024)
  79. Dittadi R, Corbetta S, Banfi G, Bertoldo F, Migliaccio S, Gonnelli S et al. Documento congiunto di SIBIOC, della Società Italiana dell’Osteoporosi, del Metabolismo Minerale e delle Malattie dello Scheletro (SIOMMMS), della Sezione Italiana della European Ligand Assay Society (ELAS), e della Associazione Medici Endocrinologi (AME) relativo alla nota AIFA 96 sulla prescrivibilità dei farmaci per la carenza di Vitamina D, e raccomandazioni per la refertazione. Biochim Clin 2020;44:400-6.
  80. Tripepi G, Fusaro M, Arcidiacono G, Sella S, Giannini S. Evaluating benefit from vitamin D supplementation: defining the area for treatment. Osteoporos Int 2023;34:1531-3.
  81. Cummings SR, Rosen C. VITAL findings – a decisive verdict on vitamin D supplementation. New Engl J Med 2022;387:368-70.
  82. Takács I, Tóth BE, Szekeres L, SzabóB, Bakos B,  Lakatos P. Randomized clinical trial to comparing efficacy of daily, weekly and monthly administration of vitamin D (3). Endocrine 2017;55:60-5.
  83. Lv Q-B, Gao X, Liu X, Shao ZX,  Xu QH,Tang L et al. The serum 25-hydroxyvitamin D levels and hip fracture risk: a meta-analysis of prospective cohort studies. Oncotarget 2017;8:39849-58.
  84. Stroomberg HV, Vojdeman FJ, Madsen CM, Helgstrand JT, Schwarz P, Heegaard AM, et al. Vitamin D levels and the risk of prostate cancer and prostate cancer mortality. Acta Oncol 2021;60:316-22.
  85. Cavalier E, Makris K, Heijboer AC, Herrmann M, Souberbielle JC. Vitamin D: analytical advances, clinical impact, and ongoing debates on health perspectives. Clin Chem. doi: 10.1093/clinchem/hvae056. (ahead of print)
  86. Bertoldo F, Cianferotti L, Colao A, Dittadi R, Giannini S, Lombardi G et al. Proposta per la refertazione della Vitamina D. Documento di consenso intersocietraio SIBIoC, SIOMMMS, ELAS, GIBIS, AME, SIR, SIMI, ORTOMED. Biochim Clin 2024;48:xx-xx.